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In this issue of Chemistry & Biology, Francisco Mal-
partida and colleagues [1] report the formation of
novel polyene amide derivatives upon transformation
of the producer strain with SCP2*-derived vectors
carrying the erythromycin resistance gene ermE. This
unexpected finding provides a new tool for generat-
ing antifungal drugs by biotransformation.
Over the last two decades, infections caused by fungi
have emerged as a growing threat to human health, es-
pecially in persons whose immune systems are com-
promised in some way. Human immunodeficiency virus
infection, leukemia, immunosuppressive therapy, organ
transplantation, and cancer chemotherapy contribute
to the continuous increase of these numbers. Several
classes of agents have been or are currently being eval-
uated for use in the treatment of invasive mycoses [2,
3], but despite this potentially wide arsenal of antifun-
gal drugs, only a few agents are currently in use; these
include the polyenes, the fluorocytosine, and the azole
derivatives. One important problem preventing suc-
cessful antifungal therapy is the dramatic increase in
drug resistance, particularly against azole antimycotics
and fluorocytosine [2], and this leaves polyene macro-
lides as the drugs of choice, since resistance to these
agents is still a rare event. Polyenes, however, show
toxic side effects and poor solubility in water; therefore,
there is an urgent need for new, safer, broad-spectrum
antifungal antibiotics with improved properties.
Polyene antibiotics are produced mainly by Strepto-
myces, a class of soil-dwelling filamentous bacteria.
They are characterized by a hydroxylated macrocyclic
lactone ring of amphipathic nature normally containing
one sugar (few polyenes have no sugars, and others
have two), but their distinct characteristic is the pres-
ence of a chromophore formed by a system of three to
seven conjugated double bonds in the macrolactone
ring [3]. This chromophore is responsible for the char-
acteristic physicochemical properties of these anti-
fungals, including strong UV-visible light absorption,
photolability, and poor water solubility. It is generallyaccepted that the antifungal activity of polyenes is the
result of binding to cytoplasmic membrane sterols [4],
although the exact mechanism that drives the interac-
tion is not fully understood. It has been proposed that
polyenes interact with membrane sterols to form com-
plexes sustained by hydrophobic interaction between
the hydrophobic portion of the polyene (chromophore
region) and the sterol, as a result yielding transmem-
brane channels [5, 6], which are responsible for the
leakage of inorganic phosphate, small molecules, and
monovalent ions, particularly K+, thus resulting in cell
death.
Polyenes belong to the ample and diverse group of
macrolides, a class of macrocyclic polyketides [7, 8],
and as such, they are synthesized by the sequential
assembly of carbon chains from small acyl precursors,
in a fashion that mechanistically resembles fatty acid
biosynthesis. However, whereas in fatty acid biosynthe-
sis each successive elongation step is followed by a
complete sequence of reactions including ketoreduc-
tion, dehydration, and enoylreduction, in the synthesis
of polyenes and other macrolides, the product of each
decarboxylating condensation may undergo all, some,
or none of the above-mentioned modifications. As a re-
sult, ketones, hydroxyl groups, double bonds, and sat-
urated chains appear at defined positions of the poly-
ketide chain. This process is catalyzed by a complex
enzymatic system, the polyketide synthase (PKS). Poly-
ene synthases are of a modular nature, being com-
posed by multifunctional polypeptides that contain sets
(or modules) of enzymatic domains for the condensa-
tion and reduction steps [9]. Each domain is generally
used at a unique step in the biosynthesis, and the ex-
tent of processing depends upon the functional do-
mains operating at a given cycle. There is, therefore, a
direct correspondence between the catalytic domains
present in the modules and the structure of the result-
ing polyketide product, which provides a powerful
model for the rational design and engineered biosyn-
thesis of novel polyketides through genetic manipula-
tion [10, 11]. Biosynthesis can be initiated by using acyl
CoA from primary metabolism as starter unit, but in
other cases starters such as acetate and propionate
can be generated by decarboxylation of malonyl and
methylmalonyl groups attached to the so-called load-
ing modules of PKSs. Other more unusual starter units
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sprimers [12].
Once the polyene macrolide core has been formed, s
vit undergoes a series of post-PKS enzymatic reactions
to yield the final bioactive compound. In comparison P
cwith other macrolides, polyenes undergo few post-PKS
modifications, but they usually require the addition of (
tthe special aminosugar mycosamine. It is also common
to find a carboxyl group near the glycosylation site that s
tis generated by oxidation of an exocyclic methyl
branch, and some hydroxyl or epoxide groups in the t
cpolyol region that are not introduced by the PKS. In
order to introduce these modifications on the agly- i
dcones resulting from the PKS, the polyene biosynthetic
clusters express several genes required for mycos-
namine biosynthesis and glycosylation, and one or more
genes (coding for cytochrome P450 monooxygenases g
fand ferredoxins) needed for the specific oxidation of
selected positions of the macrolactone ring [9]. i
fThe group led by Malpartida has investigated the ge-
netic basis for the biosynthesis of two closely related b
polyenes, the tetraenes rimocidin and CE-108 in Strep-
tomyces diastaticus var. 108 [13]. Both are derived from J
the same biosynthetic pathway, and only differ in the I
nature of the starting unit, acetyl-CoA for CE-108 or bu- P
tyryl-CoA for rimocidin. This means that the loading A
module is capable of making a choice between two dif- y
ferent starter units, a rare peculiarity that has also been F
reported for the avermectin synthase loading module U
[14]. Such versatility prompted Malpartida and col- 2
leagues to manipulate the gene, rimA, that codes for S
the loading module PKS. The gene was thus cloned
into a low copy-number Streptomyces vector (pIJ922,
San SCP2*-derivative) together with the erythromycin re-
sistance gene ermE for the selection of recombinants,
and upon transformation of either the parental strain
or a rimA-disrupted mutant, two novel tetraenes were
detected and chemically characterized as the amides
of the parental carboxylic acid tetraenes naturally pro-
duced by S. diastaticus. This finding was totally unex-
pected, since according to the canonical biosynthetic
model, no involvement could be predicted for RimA in
the formation of the carboxylic group. Further investi-
gation led to the realization that the generation of the
new molecules was actually triggered by the introduc-
tion of certain SCP2*-derived vectors, such as pIJ922
or pIJ941, containing the ermE gene and that both ge-
netic elements were required [1]. Excitingly, both com-
pounds are bioactive and show increased antifungal 1
activity and reduced hemolytic effect compared to their 1
parental molecules.
1The authors propose two plausible mechanisms to
explain the formation of the new metabolites. In one, a
1putative amidotransferase that is poorly expressed un-
der natural conditions would be used as a tailoring en-
1
zyme. This is an interesting possibility, although given
that the amide derivatives show higher antifungal activ- 1
ity than their parental molecules, one could expect thatvolution would have favored a higher expression of
uch enzyme. Surprisingly, in nature the occurrence of
uch modifications is rare. The second explanation in-
olves the use of malonamyl-CoA by module 7 of the
KS instead of methylmalonyl-CoA through a nonde-
arboxylating Claisen condensation. This would imply
1) a broad specificity for module 7 acyl carrier protein
ransacylase domain (AT), being able to accept both
ubstrates, a property not previously observed for ex-
ender ATs [15], and (2) the ability of module 7 ketosyn-
hase domain to catalyze two different types of Claisen
ondensation (decarboxylating and nondecarboxylat-
ng) depending on the substrate, also an unprece-
ented feature.
Obviously, we are far from understanding the mecha-
ism that drives the conversion of the free carboxylic
roup into an amide, and this is an exciting challenge
or the future. If such a mechanism proves to be present
n strains that produce polyenes carrying carboxyl
unctionalities, the generation of amide derivatives will
ecome a straightforward process.
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